This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Diabetic Retinopathy  • Pediatric Ophthalmology  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Ophthalmol. 2003;121:1769-1771.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

FOR SOME time retinopathy of prematurity (ROP) has been the subject of intense research activity. Experimental studies have increased our understanding of normal and abnormal retinal vascular development particularly with respect to the roles of oxygen-influenced vascular endothelial growth factor^1-2 that works synergistically with oxygen-independent insulinlike growth factor 1.³ A low serum insulinlike growth factor 1 level is said to predict ROP.³ However, insulinlike growth factor 1 is expressed by many tissues and the low serum level, therefore, could be a general marker of a sick infant at risk of ROP rather than a specific marker for retinal disease.⁴ Oxygen remains firmly center stage in ROP pathogenesis, and concomitant with basic studies, neonatal research is exploring the safe upper and lower limits of arterial oxygen saturation. Looking first at higher levels, a randomized controlled trial, comparing arterial oxygen saturation ranges of 91% to 94% with 95% to 98%, reported no . . . [Full Text of this Article]

Alistair R. Fielder, FRCP, FRCOphth
London, England

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Revised Indications for the Treatment of Retinopathy of Prematurity: Results of the Early Treatment for Retinopathy of Prematurity Randomized Trial
Early Treatment for Retinopathy of Prematurity Cooperative Group
Arch Ophthalmol. 2003;121(12):1684-1694.
ABSTRACT | FULL TEXT  

Risk Analysis of Prethreshold Retinopathy of Prematurity
Robert J. Hardy, Earl A. Palmer, Velma Dobson, C. Gail Summers, Dale L. Phelps, Graham E. Quinn, William V. Good, and Betty Tung
Arch Ophthalmol. 2003;121(12):1697-1701.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diagnosis of Plus Disease in Retinopathy of Prematurity Using Retinal Image multiScale Analysis
Gelman et al.
IOVS 2005;46:4734-4738.
ABSTRACT | FULL TEXT  

Clinical Application of the Revised Indications for the Treatment of Retinopathy of Prematurity
Jalali et al.
Arch Ophthalmol 2005;123:407-408.
FULL TEXT